100 related articles for article (PubMed ID: 8305790)
1. Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.
Ben-Joseph R; Segal R; Russell WL
Ann Pharmacother; 1993 Dec; 27(12):1532-7. PubMed ID: 8305790
[TBL] [Abstract][Full Text] [Related]
2. Use of i.v. cimetidine, ranitidine, and famotidine in 40 hospitals.
Segal R; Russell WL; Oh T; Ben-Joseph R
Am J Hosp Pharm; 1993 Oct; 50(10):2077-81. PubMed ID: 8238052
[TBL] [Abstract][Full Text] [Related]
3. Gastroesophageal reflux and histamine2 antagonists.
Bell SG
Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
[No Abstract] [Full Text] [Related]
4. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
5. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals.
Kowalsky SF; Hamilton RA; Figge HL
Hosp Formul; 1991 Sep; 26(9):725-6, 732, 734-6 passim. PubMed ID: 10114004
[TBL] [Abstract][Full Text] [Related]
6. Adverse reactions to H2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status.
Andersen M; Schou JS
Pharmacol Toxicol; 1991 Oct; 69(4):253-8. PubMed ID: 1683484
[TBL] [Abstract][Full Text] [Related]
7. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
Oh T; Franko TG
Am J Hosp Pharm; 1990 Jul; 47(7):1547-51. PubMed ID: 2114789
[TBL] [Abstract][Full Text] [Related]
8. Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.
Ahmadi A; Ebrahimzadeh MA; Ahmad-Ashrafi S; Karami M; Mahdavi MR; Saravi SS
Fundam Clin Pharmacol; 2011 Feb; 25(1):72-9. PubMed ID: 20070855
[TBL] [Abstract][Full Text] [Related]
9. [Comparative studies on hemodynamic effects of intravenous cimetidine, ranitidine and famotidine in intensive care unit patients].
Omote K; Namiki A; Sumita S; Takahashi T; Ujike Y; Hagiwara T
Masui; 1987 Jun; 36(6):940-7. PubMed ID: 2888909
[No Abstract] [Full Text] [Related]
10. Comparative effects of H2-receptor antagonists on subjective and objective assessments of sleep.
Orr WC; Duke JC; Imes NK; Mellow MH
Aliment Pharmacol Ther; 1994 Apr; 8(2):203-7. PubMed ID: 8038352
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Slichenmyer WJ; Donehower RC; Chen TL; Bowling MK; McGuire WP; Rowinsky EK
Cancer Chemother Pharmacol; 1995; 36(3):227-32. PubMed ID: 7781143
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the hemodynamic effects of oral cimetidine, ranitidine, and famotidine as determined by echocardiography.
Welage LS; Dunn-Kucharski VA; Berardi RR; Shea MJ; Dechert RE; Bleske BE
Pharmacotherapy; 1995; 15(2):158-63. PubMed ID: 7624262
[TBL] [Abstract][Full Text] [Related]
13. Ranitidine pharmacokinetics and adverse central nervous system reactions.
Slugg PH; Haug MT; Pippenger CE
Arch Intern Med; 1992 Nov; 152(11):2325-9. PubMed ID: 1444693
[TBL] [Abstract][Full Text] [Related]
14. Effect of the H2 histamine receptor antagonist on oxygen metabolism in some morphotic blood elements in patients with ulcer disease.
Kedziora-Kornatowska K; Tkaczewski W; Blaszczyk J; Buczynski A; Chojnacki J; Kedziora J
Hepatogastroenterology; 1998; 45(19):276-80. PubMed ID: 9496526
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
Saha N; Sachdev A; Bhasin DK; Sankaranahyanan A; Khosla PP; Singh K; Sharma PL
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):322-5. PubMed ID: 8103763
[TBL] [Abstract][Full Text] [Related]
16. Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man.
Kawai K
Gastroenterol Jpn; 1992 Jun; 27(3):418-23. PubMed ID: 1624085
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of H2-receptor antagonists on drug interaction in rats.
Lin JH; Cocchetto DM; Yeh KC; Duggan DE
Drug Metab Dispos; 1986; 14(6):649-53. PubMed ID: 2877821
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of H2-receptor antagonists: current status of famotidine.
Levine JB
J Int Med Res; 1989; 17 Suppl 1():48A-53A. PubMed ID: 2566543
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral H2-receptor antagonists on left ventricular systolic function and exercise capacity in patients with chronic stable heart failure.
Lucas BD; Williams MA; Mohiuddin SM; LaMadrid LJ; Schroeder LJ; Hilleman DE
Pharmacotherapy; 1998; 18(4):824-30. PubMed ID: 9692655
[TBL] [Abstract][Full Text] [Related]
20. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing.
Khasawneh SM; Affarah HB
Am J Gastroenterol; 1992 Sep; 87(9):1180-2. PubMed ID: 1519576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
